



Mechanisms of Melanoma Progression

Guest Editor:

Dr. Mohamed Hassan

1. Research Laboratory of
Surgery-Oncology, Department
of Surgery, Tulane University
School of Medicine, New Orleans,
LA 70112, USA

2. Institut National de la Santé et
de la Recherche Médicale, S1121,
University of Strasbourg, 67000
Strasbourg, France

Deadline for manuscript
submissions:

closed (1 May 2024)

Message from the Guest Editor

Dear Colleagues,

Melanoma progression, metastasis and drug resistance are not only driven by irreversible genetic instability, but also by reversible and functional reprogramming of signaling routes. PI3K, together with downstream dependent and/or converged routes, is able to mediate extra- or intra-transduction signals, leading to the initiation of tumor development, progression and resistance.

The aim of this Special Issue is to update the current findings addressing the role of receptor and non-receptor tyrosine kinases in melanoma progression and treatment resistance.

Dr. Mohamed Hassan

Guest Editor





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI